Also called:
Xofigo is a radiopharmaceutical that is FDA approved for treatment of symptomatic, metastatic castration resistant prostate cancer (mCRPC). It localizes to bone and can be used to treat patients with bone metastasis and no sites of metastatic disease it the lymph nodes or visceral organs.
